Enhanced Fusion Protein-Based Cancer Treatment System

A novel system for cancer treatment that combines a fusion protein dimer comprising CD80 and IL-2 proteins with an anticancer agent, featuring sustained release formulation, modified half-life, and personalized treatment options to enhance immune activity and reduce toxicity.

The original patent disclosed a pharmaceutical composition for cancer treatment comprising a fusion protein dimer and an anticancer agent. However, the composition's effectiveness was limited by its short half-life, lack of sustained release, and potential toxicity. The new inventive concept addresses these limitations by introducing sustained release formulations, modified half-life, and personalized treatment options to enhance immune activity and reduce toxicity.

The new system comprises a fusion protein dimer comprising CD80 and IL-2 proteins, which is administered in a sustained release formulation to enhance immune activity over an extended period. The fusion protein dimer can be modified to have a longer half-life, allowing for more efficient treatment. Additionally, the system can be adapted for personalized cancer treatment by detecting and responding to the specific genetic profile of a patient's cancer cells. The system can also be combined with an immune checkpoint inhibitor to further enhance the immune response. Furthermore, the system can be designed to target specific cancer cells and minimize damage to healthy cells, reducing toxicity.

The new claims introduce novel and non-obvious features, including sustained release formulations, modified half-life, and personalized treatment options, which significantly enhance the effectiveness and safety of the original pharmaceutical composition.

Alternative embodiments of the system could include different sustained release formulations, such as nanoparticles or liposomes, or different methods for modifying the half-life of the fusion protein dimer. Additionally, the system could be adapted for use with different types of cancer or combined with other therapies, such as chemotherapy or radiation therapy.

The enhanced fusion protein-based cancer treatment system has significant commercial potential in the oncology market, with potential applications in various types of cancer, including solid tumors and hematological malignancies. The system's ability to enhance immune activity and reduce toxicity makes it an attractive option for patients and healthcare providers.